On the recordMarch 31, 2022
I thank the gentleman for yielding. First of all, this is not price control. It is limiting the purchaser on a price, but the companies are still going to charge what they are going to charge, and somebody is going to have to pay, and Medicare is going to have to pay. So, it does increase the cost. But it is not price control on the pharmaceuticals. And I want to say that we have a bill, of course, that will allow negotiation in Medicare, just as the VA does. {time} 1430 Negotiation is not price control. Negotiation is saying, I am going to buy a lot of your product, and I want a better price. A lot of us do that. We call it Sam's Club, or some other club that we go to. And we buy large volumes and get a cheaper price than our poorer friends who just buy it one at a time. So I am for this bill. It is a good bill. Madam Speaker, I thank Representatives Craig, Kildee, and McBath for their leadership on this bill. They have long been champions of making healthcare and prescription medications accessible and affordable for all Americans. More than one in three Americans are at high risk of developing diabetes, and over 37 million Americans already have it. A lot of those folks can't do without insulin. They don't have an option. And insulin has been on the market for decades and is not protected under patent, and the development prices have ages ago been amortized.…





